{"created":"2023-06-20T13:45:25.966672+00:00","id":190,"links":{},"metadata":{"_buckets":{"deposit":"5483014a-184e-4a62-ad66-d834c3de9439"},"_deposit":{"created_by":12,"id":"190","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"190"},"status":"published"},"_oai":{"id":"oai:khsu.repo.nii.ac.jp:00000190","sets":["22:81:84"]},"author_link":["323","322","319"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"15","bibliographicPageEnd":"26","bibliographicPageStart":"19","bibliographic_titles":[{"bibliographic_title":"熊本保健科学大学研究誌"},{"bibliographic_title":"Journal of Kumamoto Health Science University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"アルツハイマー病克服のアプローチの一つとして，アミロイドβをターゲットとしたワクチ\nン開発が進められている。過去，全長のアミロイドβペプチドにサポニンをアジュバントとし\nて加えたワクチンの臨床試験が行われたが，細胞性免疫によると考えられる髄膜脳炎が出現し，\n中止となった。その原因は全長のアミロイドβペプチド内のＴ細胞エピトープ，アジュバント\nにあったと考えられている。従って有効で安全なアミロイドβペプチドアジュバントの組み合\nわせの開発が望まれている。これまでに我々は細胞性免疫を誘導する可能性がある配列を除い\nた改変アミロイドβペプチドにシステインを付加することで高い抗体産生能を示すことを見出\nし報告した。今回，脂質異常治療薬のシステイン付加アミロイドβペプチドワクチンに対する\nアジュバント効果を検討した。脂質異常治療薬はスタチン類，小腸コレステロールトランスポー\nター阻害剤，フィブラート類およびビグアナイド系薬剤を用いた。その結果，いずれにおいて\nもシステイン付加アミロイドβペプチドワクチンに対するアジュバント効果が認められ，特に\nロバスタチン，イコサベント酸エチル，ベザフィブラートはAlum アジュバントと比較しても\n高いアジュバント効果を示した。以上の結果から，脂質異常治療薬は高い抗体産生誘導能を示\nすことが判った。アルツハイマー病ワクチン開発において脂質異常治療薬は有望なアジュバン\nト候補の一つになり得ると考えられる。","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"熊本保健科学大学"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"24335002","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"松田, 純一"}],"nameIdentifiers":[{"nameIdentifier":"322","nameIdentifierScheme":"WEKO"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"上仲, 一義","creatorNameLang":"ja"}],"familyNames":[{"familyName":"上仲","familyNameLang":"ja"}],"givenNames":[{"givenName":"一義","givenNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"323","nameIdentifierScheme":"WEKO"}]},{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"野崎, 周英","creatorNameLang":"ja"}],"familyNames":[{"familyName":"野崎","familyNameLang":"ja"}],"givenNames":[{"givenName":"周英","givenNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"319","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-06-06"}],"displaytype":"detail","filename":"03-matsuda-p019-026.pdf","filesize":[{"value":"1.6 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"03-matsuda-p019-026","url":"https://khsu.repo.nii.ac.jp/record/190/files/03-matsuda-p019-026.pdf"},"version_id":"9bab1cff-c7be-4312-84da-7b6303dd87fd"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"アルツハイマー病","subitem_subject_scheme":"Other"},{"subitem_subject":"ワクチン","subitem_subject_scheme":"Other"},{"subitem_subject":"アジュバント","subitem_subject_scheme":"Other"},{"subitem_subject":"アミロイドβ","subitem_subject_scheme":"Other"},{"subitem_subject":"脂質異常治療薬","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"アルツハイマー病ワクチンに用いるアジュバントの研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"アルツハイマー病ワクチンに用いるアジュバントの研究"},{"subitem_title":"Research of adjuvants for Alzheimerʼs disease vaccine","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"12","path":["84"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-07"},"publish_date":"2018-06-07","publish_status":"0","recid":"190","relation_version_is_last":true,"title":["アルツハイマー病ワクチンに用いるアジュバントの研究"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2024-04-15T07:27:31.976872+00:00"}